Latest Merck & Company (MRK) Headlines
How To Understand And Use IBD's Dividend Screens
at Investor's Business Daily - Thu Mar 13, 3:01PM CDT
When IBD revamped its Income Investor column several months back, it introduced three screens aimed at successful dividend investing. They are the backbone of the column. Most of the companies covered in this daily column (today on Page B9) are...
Global Biosimilar Market Outlook 2018
PR Newswire - Thu Mar 13, 3:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/34kmnx/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Merck (MRK) Breaks Through Support at $56.40
Comtex SmarTrend(R) - Thu Mar 13, 11:45AM CDT
Shares of Merck (NYSE:MRK) have bearishly opened below the pivot of $56.67 today and have reached the first support level of $56.40. Should the shares continue to fall, the support pivots of $56.00 and $55.33 will be of interest.
MRK May 2nd Options Begin Trading
at The Street - Thu Mar 13, 10:53AM CDT
Investors in Merck & Co., Inc saw new options become available today, for the May 2nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK options chain for the new May 2nd contracts and identified one put...
Merck Up 14.5% Since SmarTrend Uptrend Call (MRK)
Comtex SmarTrend(R) - Thu Mar 13, 10:10AM CDT
SmarTrend identified an Uptrend for Merck (NYSE:MRK) on December 26th, 2013 at $49.56. In approximately 3 months, Merck has returned 14.50% as of today's recent price of $56.74.
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
Study: Pfizer vaccine cuts pneumonia in elderly
By LINDA A. JOHNSON - AP - Wed Mar 12, 5:19PM CDT
TRENTON, N.J. (AP) — Pfizer Inc. said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators.
Can Biogen Catch up to Merck in Alzheimer's Race?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Drug development is a risky enterprise on its own. Advancing a safe and effective therapy for Alzheimer's disease (AD) is like trying to shoot the moon with a slingshot, blindfolded. The exact mechanism behind the formation of memories isn't entirely...
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Is Merck a Buy at Current Price Levels?
Peter Stephens, The Motley Fool - Motley Fool - Tue Mar 11, 7:58PM CDT
Shares in Merck have had a strong three months, up 15% while the S&P 500 has posted gains of just under 4%. However, since the bull market of March 2009 kicked off five years ago, Merck is considerably behind the wider index. While the S&P...
Watch for Merck to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Tue Mar 11, 3:55PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.57 to a high of $57.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $57.00 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.10%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Tue Mar 11, 3:55PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.57 to a high of $57.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $57.00 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Codexis Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:04PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Medical groups question price of new hep C drug
By MATTHEW PERRONE - AP - Tue Mar 11, 1:18PM CDT
WASHINGTON (AP) — An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc.
Critical Alerts For Blackberry, Sohu.com, Ross Stores, Merck, and Peabody Energy By InvestorsObserver
PR Newswire - Tue Mar 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBRY, SOHU, ROST, MRK, and BTU.
New Corporations Join Growing WEConnect International Community
PRWeb - Tue Mar 11, 5:03AM CDT
WEConnect International is pleased to announce that AIG, Access Bank, and Merck are joining as global members of WEConnect International.
This Massive Hedge Fund Company Has Been Buying Citigroup, Merck, and Hertz
Selena Maranjian, The Motley Fool - Motley Fool - Mon Mar 10, 4:00PM CDT
The latest 13F season is here, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling. ...
How To Understand And Use IBD's Dividend Screens
at Investor's Business Daily - Thu Mar 13, 3:01PM CDT
When IBD revamped its Income Investor column several months back, it introduced three screens aimed at successful dividend investing. They are the backbone of the column. Most of the companies covered in this daily column (today on Page B9) are...
Global Biosimilar Market Outlook 2018
PR Newswire - Thu Mar 13, 3:00PM CDT
Research and Markets (http://www.researchandmarkets.com/research/34kmnx/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Merck (MRK) Breaks Through Support at $56.40
Comtex SmarTrend(R) - Thu Mar 13, 11:45AM CDT
Shares of Merck (NYSE:MRK) have bearishly opened below the pivot of $56.67 today and have reached the first support level of $56.40. Should the shares continue to fall, the support pivots of $56.00 and $55.33 will be of interest.
MRK May 2nd Options Begin Trading
at The Street - Thu Mar 13, 10:53AM CDT
Investors in Merck & Co., Inc saw new options become available today, for the May 2nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK options chain for the new May 2nd contracts and identified one put...
Merck Up 14.5% Since SmarTrend Uptrend Call (MRK)
Comtex SmarTrend(R) - Thu Mar 13, 10:10AM CDT
SmarTrend identified an Uptrend for Merck (NYSE:MRK) on December 26th, 2013 at $49.56. In approximately 3 months, Merck has returned 14.50% as of today's recent price of $56.74.
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.
Study: Pfizer vaccine cuts pneumonia in elderly
By LINDA A. JOHNSON - AP - Wed Mar 12, 5:19PM CDT
TRENTON, N.J. (AP) — Pfizer Inc. said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators.
Can Biogen Catch up to Merck in Alzheimer's Race?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 12, 1:30PM CDT
Drug development is a risky enterprise on its own. Advancing a safe and effective therapy for Alzheimer's disease (AD) is like trying to shoot the moon with a slingshot, blindfolded. The exact mechanism behind the formation of memories isn't entirely...
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Is Merck a Buy at Current Price Levels?
Peter Stephens, The Motley Fool - Motley Fool - Tue Mar 11, 7:58PM CDT
Shares in Merck have had a strong three months, up 15% while the S&P 500 has posted gains of just under 4%. However, since the bull market of March 2009 kicked off five years ago, Merck is considerably behind the wider index. While the S&P...
Watch for Merck to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Tue Mar 11, 3:55PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.57 to a high of $57.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $57.00 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.10%, Merck Offers Investors Better Value
Comtex SmarTrend(R) - Tue Mar 11, 3:55PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $56.57 to a high of $57.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $57.00 on volume of 10.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Codexis Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Mar 11, 3:04PM CDT
Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Medical groups question price of new hep C drug
By MATTHEW PERRONE - AP - Tue Mar 11, 1:18PM CDT
WASHINGTON (AP) — An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences Inc.
Critical Alerts For Blackberry, Sohu.com, Ross Stores, Merck, and Peabody Energy By InvestorsObserver
PR Newswire - Tue Mar 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBRY, SOHU, ROST, MRK, and BTU.
New Corporations Join Growing WEConnect International Community
PRWeb - Tue Mar 11, 5:03AM CDT
WEConnect International is pleased to announce that AIG, Access Bank, and Merck are joining as global members of WEConnect International.
This Massive Hedge Fund Company Has Been Buying Citigroup, Merck, and Hertz
Selena Maranjian, The Motley Fool - Motley Fool - Mon Mar 10, 4:00PM CDT
The latest 13F season is here, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling. ...
